Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 419

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 419
---
 States.

Risks
Related to Our Operations and Financial Condition

We
are an early development-stage company with no revenues.

As
very early development-stage enterprise that is focused on the development of a pre-clinical pharmaceutical product, we have generated
no revenue and have an accumulated deficit of $30.6 million and $14.1 million as of December 31, 2024 and December 31, 2023, respectively.
There can be no assurance that sufficient funds required to pursue our development program will be generated from operations or that
funds will be available from external sources, such as debt or equity financings or other potential sources. The lack of additional capital
resulting from the inability to generate cash flow from operations, or to raise capital from external sources would force us to substantially
curtail or cease operations and would, therefore, have a material adverse effect on business. Furthermore, there can be no assurance
that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect
on our existing stockholders. It is for these reasons substantial doubt about our ability to continue as a going concern exists and an
explanatory paragraph relating to our ability to continue as a going concern can be found within the report of our independent registered
public accounting firm on our audited financial statements for the fiscal year ended December 31, 2024.

We
seek to overcome the circumstances that impact our ability to remain a going concern in the future through the growth of revenues with
interim cash flow deficiencies being addressed through additional equity and debt financing. We anticipate raising additional funds through
public or private financing, strategic relationships, or other arrangements in the near future to support our business operations; however,
we may not have commitments from third parties for a sufficient amount of additional capital. We cannot be certain that any such financing
will be available on acceptable terms, or at all, and our failure to raise capital when needed could limit our ability to continue operations.
Our ability to obtain additional funding will determine our ability to continue as a going concern. Failure to secure additional financing
in a timely manner and on favorable terms would have a material adverse effect on our financial performance, results of operations and
stock price and require us to curtail or cease operations, sell off our assets, seek protection from our creditors through bankruptcy
proceedings, or otherwise. Furthermore, additional equity financing may be dilutive to the holders of our common stock, and debt financing,